September 2016
Volume 57, Issue 12
Open Access
ARVO Annual Meeting Abstract  |   September 2016
Compliance for angiogenesis inhibitor treatment with ranibizumab in diabetic macular edema. A seven years experience in Mexican population of the Mexican Institute of Ophthalmology.
Author Affiliations & Notes
  • Ramirez Neria Paulina
    Retina and Vitreous, Instituto Mexicano de Oftalmologia I.A.P., Mexico State, DF, Mexico
  • Renata Garcia Franco
    Retina and Vitreous, Instituto Mexicano de Oftalmologia I.A.P., Mexico State, DF, Mexico
  • Brenda Rodriguez Camacho
    Instituto Mexicano de Oftalmologia I.A.P., Queretaro, Mexico
  • Kristo Aronne Lopez
    Retina and Vitreous, Instituto Mexicano de Oftalmologia I.A.P., Mexico State, DF, Mexico
  • Footnotes
    Commercial Relationships   Ramirez Neria Paulina, None; Renata Garcia Franco, None; Brenda Rodriguez Camacho, None; Kristo Aronne Lopez, None
  • Footnotes
    Support  none
Investigative Ophthalmology & Visual Science September 2016, Vol.57, 2113. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Ramirez Neria Paulina, Renata Garcia Franco, Brenda Rodriguez Camacho, Kristo Aronne Lopez; Compliance for angiogenesis inhibitor treatment with ranibizumab in diabetic macular edema. A seven years experience in Mexican population of the Mexican Institute of Ophthalmology.. Invest. Ophthalmol. Vis. Sci. 2016;57(12):2113.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Report adherence to anti-angiogenic therapy in patients with diabetic macular edema (DDME) in Mexican population treated with intravitreal ranibizumab (IVR).

Methods : We analized the medical records of the Mexican Institute of Ophthalmology in patients with diabetic macular edema who had been treated with intravitreal ranibizumab (2008 -2015).

Results : A total of 47 patients (50 eyes) with diabetic macular edema that met the inclusion criteria were found. The mean age of the patients was 61.92 ± 8.85 years. The mean best corrected visual acuity (BCVA) at diagnosis was 20/160 (0.9 logMAR). About compliance, 90% of patients received the second IVR, with a mean BCVA of 20/125 (0.8 logMAR) found at month 3. By month 3, 22% of patients didn not show up to get the IVR, and by the 6th month, 30% of patients refuse to get treatment. Even when patients refused to have the IVR, they did show up for follow up visits, with a mean 10.78 months follow up. The mean number of IVB was 4.14 (1-11 range). Central foveal thicknesses (CFT) of all patients at follow-up were averaged, regardless of the number of injections received, with a mean CFT of 302.18 μm, this is a 78.100 μm reduction compared to baseline (380.36 μm).

Conclusions : Our results exhibit a smaller number of monthly IVR compared to large clinical trails, such as those made by PACORES in hispanic population. The lack of adherence to treatment negatively influences the final BCVA and CFT of our patients, that is why, investigating the causes of this and work on improving adherence to it, would be beneficial for our population.

This is an abstract that was submitted for the 2016 ARVO Annual Meeting, held in Seattle, Wash., May 1-5, 2016.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×